Correction: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis (JAMA Oncology (2018) DOI: 10.1001/jamaoncol.2018.3923);Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

JAMA Oncology

Volumn 4, Issue 12, 2018, Pages 1721-1728

  Wang, Daniel Y ^a   Salem, Joe Elie ^a,b,c   Cohen, Justine V ^d   Chandra, Sunandana ^e   Menzer, Christian ^f   Ye, Fei ^a   Zhao, Shilin ^a   Das, Satya ^a   Beckermann, Kathryn E ^a   Ha, Lisa ^e   Rathmell, W Kimryn ^a   Ancell, Kristin K ^a   Balko, Justin M ^a   Bowman, Caitlin ^e   Davis, Elizabeth J ^a   Chism, David D ^a   Horn, Leora ^a   Long, Georgina V ^g,h,i,j   Carlino, Matteo S ^g,h,k,l   Lebrun Vignes, Benedicte ^b,c   Eroglu, Zeynep ^m   Hassel, Jessica C ^f   Menzies, Alexander M ^g,h,k,l   Sosman, Jeffrey A ^e   Sullivan, Ryan J ^d   Moslehi, Javid J ^a   Johnson, Douglas B ^a   more..

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g MELANOMA INSTITUTE AUSTRALIA   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ ROYAL NORTH SHORE HOSPITAL   (Australia)

^j Mater Hospital   (Australia)

^k Children's Hospital t Westmead   (Australia)

^l BLACKTOWN HOSPITAL   (Australia)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADRENAL DISEASE; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL OUTCOME; COLITIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG FATALITY; DRUG SURVEILLANCE PROGRAM; ELECTROLYTE DISTURBANCE; FACTUAL DATABASE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HYPOPHYSITIS; INCIDENCE; INFECTION; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE ORGAN FAILURE; MYOCARDITIS; MYOSITIS; NEPHRITIS; NEUROLOGIC DISEASE; NEUROTOXICITY; PNEUMONIA; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; SYSTEMATIC REVIEW; THROMBOSIS; THYROID DISEASE; VIGILYZE DATABASE; WORLD HEALTH ORGANIZATION; ADVERSE DRUG REACTION; ADVERSE EVENT; DRUG EFFECT; GENE; IMMUNOLOGY; IMMUNOTHERAPY; MORTALITY; NEOPLASM;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENES, CDC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INCIDENCE; NEOPLASMS; PHARMACOVIGILANCE; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES;

EID: 85053689477     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2018.5346     Document Type: Erratum

References (27)

1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017; 377 (14): 1345-1356. doi: 10.1056/NEJMoa1709684 28889792
2. Hammers HJ, Plimack ER, Infante JR, Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 Study. J Clin Oncol. 2017; 35 (34): 3851-3858. doi: 10.1200/JCO.2016.72.1985 28678668
3. Hellmann MD, Rizvi NA, Goldman JW, Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017; 18 (1): 31-41. doi: 10.1016/S1470-2045(16)30624-6 27932067
4. Antonia SJ, López-Martin JA, Bendell J, Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17 (7): 883-895. doi: 10.1016/S1470-2045(16)30098-5 27269741
5. Motzer RJ, Tannir NM, McDermott DF,; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018; 378 (14): 1277-1290. doi: 10.1056/NEJMoa1712126 29562145
6. Postow MA, Sidlow R, Hellmann MD. Immune-Related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018; 378 (2): 158-168. doi: 10.1056/NEJMra1703481 29320654
7. Hassel JC, Heinzerling L, Aberle J, Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017; 57: 36-49. doi: 10.1016/j.ctrv.2017.05.003 28550712
8. Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol. 2018; 4 (1): 98-101. 28817755
9. Johnson DB, Balko JM, Compton ML, Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016; 375 (18): 1749-1755. doi: 10.1056/NEJMoa1609214 27806233
10. Naidoo J, Wang X, Woo KM, Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017; 35 (7): 709-717. doi: 10.1200/JCO.2016.68.2005 27646942
11. Koelzer VH, Rothschild SI, Zihler D, Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer. 2016; 4: 13. doi: 10.1186/s40425-016-0117-1 26981243
12. Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology. 2017; 6 (10): E1344805. doi: 10.1080/2162402X.2017.1344805 29123955
13. Fellner A, Makranz C, Lotem M, Neurologic complications of immune checkpoint inhibitors. J Neurooncol. 2018; 137 (3): 601-609. doi: 10.1007/s11060-018-2752-5 29332184
14. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391 (10124): 933. doi: 10.1016/S0140-6736(18)30533-6 29536852
15. Beer TM, Kwon ED, Drake CG, Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017; 35 (1): 40-47. doi: 10.1200/JCO.2016.69.1584 28034081
16. Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic facts. Drug Inf J. 2008; 42 (5): 409-419. doi: 10.1177/009286150804200501
17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009; 6 (7): E1000097. doi: 10.1371/journal.pmed.1000097 19621072
18. Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: A web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics. 2015; 16: 169. doi: 10.1186/s12859-015-0611-3 25994840
19. Pignon JP, Tribodet H, Scagliotti GV,; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26 (21): 3552-3559. doi: 10.1200/JCO.2007.13.9030 18506026
20. Gooley TA, Chien JW, Pergam SA, Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363 (22): 2091-2101. doi: 10.1056/NEJMoa1004383 21105791
21. Long GV, Weber JS, Infante JR, Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016; 34 (8): 871-878. doi: 10.1200/JCO.2015.62.9345 26811525
22. Soria JC, Ohe Y, Vansteenkiste J,; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018; 378 (2): 113-125. doi: 10.1056/NEJMoa1713137 29151359
23. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006; 244 (1): 10-15. doi: 10.1097/01.sla.0000217673.04165.ea 16794383
24. Bailey SH, Bull DA, Harpole DH, Outcomes after esophagectomy: A ten-year prospective cohort. Ann Thorac Surg. 2003; 75 (1): 217-222. doi: 10.1016/S0003-4975(02)04368-0 12537219
25. Weber J, Mandala M, Del Vecchio M,; CheckMate 238 Collaborators. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017; 377 (19): 1824-1835. doi: 10.1056/NEJMoa1709030 28891423
26. Antonia SJ, Villegas A, Daniel D,; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017; 377 (20): 1919-1929. doi: 10.1056/NEJMoa1709937 28885881
27. Betof AS, Nipp RD, Giobbie-Hurder A, Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist. 2017; 22 (8): 963-971. doi: 10.1634/theoncologist.2016-0450 28476944